Patient costs of hypertension care in public health care facilities in Kenya

Abstract

Summary Background Hypertension in low‐ and middle‐income countries, including Kenya, is of economic importance due to its increasing prevalence and its potential to present an economic burden to households. In this study, we examined the patient costs associated with obtaining care for hypertension in public health care facilities in Kenya. Methods We conducted a cross‐sectional study among adult respondents above 18 years of age, with at least 6 months of treatment in two counties. A total of 212 patients seeking hypertension care at five public facilities were interviewed, and information on care seeking and the associated costs was obtained. We computed both annual direct and indirect costs borne by these patients. Results Overall, the mean annual direct cost to patients was US$ 304.8 (95% CI, 235.7‐374.0). Medicines (mean annual cost, US$ 168.9; 95% CI, 132.5‐205.4), transport (mean annual cost, US$ 126.7; 95% CI, 77.6‐175.9), and user charges (mean annual cost, US$ 57.7; 95% CI, 43.7‐71.6) were the highest direct cost categories. Overall mean annual indirect cost was US$ 171.7 (95% CI, 152.8‐190.5). The incidence of catastrophic health care costs was 43.3% (95% CI, 36.8‐50.2) and increased to 59.0% (95% CI, 52.2‐65.4) when transport costs were included. Conclusions Hypertensive patients incur substantial direct and indirect costs. High rates of catastrophic costs illustrate the urgency of improving financial risk protection for these patients and strengthening primary care to ensure affordability of hypertension care.

Patient costs of diabetes mellitus care in public health care facilities in Kenya

“…Similar findings have been reported by recent studies in Kenya and South Africa . Costs due to medicine have been shown to reduce adherence to medication and demand for health services by patients with NCDs . Past studies conducted in LMICs have however shown that social health insurance schemes do not comprehensively cover the costs for medicines and that OOP costs, which are majorly contributed by medicines, are a hindrance to attainment of universal health coverage in many low resource settings .…”

Socioeconomic inequalities in hypertension in Kenya: A decomposition analysis of 2015 Kenya STEPwise survey on non-communicable diseases risk factors

“…This could be due to the differences in study population. However, we hypothesize the poorest individuals faces several nancial barriers, which hinder access to health services for control and treatment of hypertension [56] due to huge out of pocket expenditure [6,57]. In addition, despite the hypertension screening and early diagnosis being key in averting hypertension, it is likely that individuals in the richest wealth quintile are screened more for high blood pressure than the poorest individuals.…”

Layering and scaling up chronic non‐communicable disease care on existing HIV care systems and acute care settings in Kenya: a cost and budget impact analysis

“…AMPATH’s CDM programme has lower average per visit costs compared to other public programs that offer chronic NCD care in Kenya, and substantially lower costs than hospitalizations related to untreated NCDs [33,34]. This difference should not disqualify the generalizability of our findings and recommends the expansion of the CDM programme.…”